Process for the preparation of and crystalline forms of optical enantiomers of modafinil
View Patent ↗The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 Å, and a process for the preparation thereof.
1. A polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 Å.
2. The polymorphic form according to claim 1 , wherein the powder X-ray diffraction spectrum further comprises intensity peaks corresponding to interplanar spacings of about 7.57, 7.44, and 3.71 Å.
3. A polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising reflections at about 15.4, 29.1 and 35.3 degrees 2θ.
4. The polymorphic form according to claim 3 , wherein the powder X-ray diffraction spectrum further comprises reflections at about 17.4, 17.7 and 35.9 degrees 2θ.
5. A composition consisting essentially of a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 Å.
6. The composition according to claim 5 , wherein the powder X-ray diffraction spectrum further comprising intensity peaks corresponding to interplanar spacings of about 7.57, 7.44, and 3.71 Å.
7. A composition consisting essentially of a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising reflections at about 15.4, 29.1 and 35.3 degrees 2θ.
8. The composition according to claim 7 , wherein the powder X-ray diffraction spectrum further comprising reflections at about 17.4, 17.7 and 35.9 degrees 2θ.
9. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a polymorphic form of (−)-modafinil as defined in claim 1 .
10. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a polymorphic form of (−)-modafinil as defined in claim 2 .
11. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a polymorphic form of (−)-modafinil as defined in claim 3 .
12. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a polymorphic form of (−)-modafinil as defined in claim 4 .
13. A process for preparing the polymorph of (−)-modafinil of claim 1 , comprising the steps of:
(a) providing a solution of (−)-modafinil dissolved in a hot solvent;
(b) cooling the solution from step (a) to produce crystals;
(c) filtering the crystals;
(d) drying the crystals; and
(e) obtaining the crystals of said polymorph of (−)-modafinil,
wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene, and
wherein the obtained crystals are substantially free of Form I (−)-modafinil.
14. A process for preparing the polymorph of (−)-modafinil of claim 1 , comprising the steps of:
(a) providing a solution of (−)-modafinil dissolved in a hot solvent;
(b) cooling the solution from step (a) to produce crystals;
(c) filtering the crystals;
(d) drying the crystals; and
(e) obtaining the crystals of said polymorph of (−)-modafinil,
wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene, and
wherein the obtained crystals are substantially free of Form IV (−)-modafinil.
15. A process for preparing the polymorph of (−)-modafinil of claim 1 , comprising the steps of:
(a) providing a solution of (−)-modafinil dissolved in a hot solvent;
(b) cooling the solution from step (a) to produce crystals;
(c) filtering the crystals;
(d) drying the crystals; and
(e) obtaining the crystals of said polymorph of (−)-modafinil,
wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene, and
wherein the obtained crystals are substantially free of Form V (−)-modafinil.
16. A process for preparing the polymorph of (−)-modafinil of claim 1 , comprising the steps of:
(a) providing a solution of (−)-modafinil dissolved in a hot solvent;
(b) cooling the solution from step (a) to produce crystals;
(c) filtering the crystals;
(d) drying the crystals; and
(e) obtaining the crystals of said polymorph of (−)-modafinil,
wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene, and
wherein the obtained crystals are substantially free of Forms I, IV and V (−)-modafinil.
17. A process for preparing the polymorph of (−)-modafinil of claim 1 , comprising the steps of:
(a) providing a solution of (−)-modafinil dissolved in a hot solvent;
(b) cooling the solution from step (a) to produce crystals;
(c) filtering the crystals;
(d) drying the crystals; and
(e) obtaining the crystals of said polymorph of (−)-modafinil,
wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene, and
wherein the obtained crystals are substantially free of other polymorphic forms of (−)-modafinil.
18. A process for preparing the polymorph of (−)-modafinil of claim 1 , comprising the steps of:
(a) providing a solution of (−)-modafinil dissolved in a hot solvent;
(b) cooling the solution from step (a) to produce crystals;
(c) filtering the crystals;
(d) drying the crystals; and
(e) obtaining the crystals of said polymorph of (−)-modafinil,
wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene.